In conversation with Philippa Easterbrook, Global Hepatitis Programme, at the World Health Organization:

Philippa talks to the Medicines Patent Pool about the progress made in hepatitis treatment and how in six years they have overcome major challenges, and working with countries and partners are now seeing major achievements in this space.

This video was recorded before COVID-19 pandemic hit. Since then, hepatitis drugs based on sofosbuvir/daclatasvir (SOF/DAC) have shown potential to treat SARS-CoV-2 in small trials in Iran. While larger trials are underway, the fight against both SARS-CoV-2 and HCV continues.

For more information on the WHO Global Hepatitis Programme